Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
Institut National de la Santé Et de la Recherche Médicale, France
Patients will be divided into 2 groups treated according to a non-intensive chemotherapy :
Group 1 : 40 patients treated with Azacytidine and Venetoclax +/- another molecule according to the following schedule:
* Azacytidine 75 mg/m² D1 to D7 SC
* Venetoclax: 400 mg/day orally in 1 dose between 14 and 28 days per cycle. The cycles will be 28 days long and will be carried out until relapse or death. Cytokine assays will be carried out on D1, D8, D15 and D22 of each cycle for 2 cycles.
Group 2 : 20 patients treated with Azacytidine +/- another molecule according to the following schedule:
• Azacytidine 75 mg/m² D1 to D7 SC The cycles will be 28 days long and will be carried out until relapse or death. The cytokine assays will be carried out on D1, D8, D15 and D22 of each cycle for 3 cycles.
The duration of follow-up for a patient is 12 months from day 1 of the first cycle.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \>=18 years
AML or SMD-HR or CMML in first line or in relapse receiving a hypomethylating agent +/- another molecule or a hypomethylating agent in combination with venetoclax +/- another molecule.
Patient having agreed to participate in the study (information note signature) and having signed the biocollection consent
You may not be if
No social security or any other regime
Pregnant women or patient unable to take contraception in case of fertility
Breastfeeding women
Minors
Adults under guardianship, curators or safeguard of justice